ReviewIndian journal of ophthalmology2022
Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.
Review in Indian journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Optical coherence tomography angiography in thyroid associated ophthalmopathy: a systematic review.BMC ophthalmology · 2024Pooled it
- IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial.JAMA ophthalmology · 2025Trial
- Combined use of orbital soft tissue volume and retinal microvessel density for diagnosing dysthyroid optic neuropathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- A Consensus-Based Clinical Activity Score Atlas for Thyroid Eye Disease in East Asian Patients: The Korean Society of Ophthalmic Plastic and Reconstructive Surgery Initiative.Korean journal of ophthalmology : KJO · 2026Article
- Development and validation of a nomogram for predicting non-response to tocilizumab in thyroid eye disease: a retrospective study.BMC ophthalmology · 2026Article
- Triglyceride-driven pathogenesis in thyroid-associated ophthalmopathy: a dual approach of clinical correlation and genetic causality.International journal of ophthalmology · 2026Article
- Quantitative analysis of orbital soft tissue for the detection of dysthyroid optic neuropathy in patients with thyroid-associated ophthalmopathy, based on three-dimensional cube fast spin-echo Flex.Quantitative imaging in medicine and surgery · 2025Article
- FOCUS-MUSE DWI outperforms MUSE and FOCUS DWIs in orbital imaging quality and staging thyroid-associated ophthalmopathy.Insights into imaging · 2025Article
- Effectiveness of intravenous glucocorticoids in active thyroid eye disease patients with low clinical activity scores.Endocrine · 2025Article
- Inflammatory Proteins Mediate the Effect of Gut Microbiota on Graves' Ophthalmopathy: A Mendelian Randomization Study.Translational vision science & technology · 2025Article
- Review
- Comparative analysis of deep learning architectures for thyroid eye disease detection using facial photographs.BMC ophthalmology · 2025Article
- Development and validation of potential molecular subtypes and signatures of thyroid eye disease based on angiogenesis-related gene analysis.BMC pharmacology & toxicology · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- Identification of key extracellular proteins as the potential biomarkers in thyroid eye disease.PloS one · 2025Article
- A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Dixon MRI-based quantitative parameters of extraocular muscles, intraorbital fat, and lacrimal glands for staging thyroid-associated ophthalmopathy.Insights into imaging · 2024Article
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (London, England) · 2024Review
- Specific static and dynamic functional network connectivity changes in thyroid-associated ophthalmopathy and it predictive values using machine learning.Frontiers in neuroscience · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid eye disease (TED) is a rare disease that can lead to decreased quality of life, permanent disfigurement, and vision loss. Clinically, TED presents with exophthalmos, periorbital edema, extraocular muscle dysfunction, and eyelid retraction, and can lead to vision-threatening complications such as exposure to keratopathy and dysthyroid optic neuropathy (DON). Over the last several years, significant advancements have been made in the understanding of its pathophysiology as well as optimal management. Ethnic variations in the prevalence, clinical presentation, and risk of vision-threatening complications of TED are summarized, and risk factors associated with TED are discussed. Additionally, significant advances have been made in the management of TED. The management of TED traditionally included anti-inflammatory medications, orbital radiation therapy, orbital surgical decompression, and biologic therapies. Most recently, targeted therapies such as teprotumumab, an insulin-like growth factor-1 receptor antagonist, have been studied in the context of TED, with promising initial data. In this review, updates in the understanding and management of TED are presented with a focus on the international variations in presentation and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.